Skip to main content

Table 2 Univariate and multivariate analyses of PFS

From: Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: an insight from clinical practice

Variable (comparator)Progression free survival
Univariate analysisMultivariate analysis
HR (95% CI)p-valueHR (95% CI)p-value
Early ir-fatigue
 Yes vs no2.25 (1.63–3.1)< 0.00012.29 (1.62–3.22)< 0.0001
Sex
 Male vs female1.05 (0.78–1.41)0.7515
Age at diagnosis
 Elderly vs non-elderly1.20 (0.91–1.58)0.1940
Primary tumor (melanoma)
 NSCLC1.51 (1.09–2.08)0.01241.08 (0.76–1.53)0.6446
 Renal cell carcinoma1.55 (1.06–2.28)0.02411.22 (0.81–1.85)0.3445
 Others1.38 (0.43–4.40)0.57900.95 (0.29–3.06)0.9336
Treatment line
 Non-first vs first1.75 (1.28–2.42)0.00051.66 (1.17–2.35)0.0041